ClinicalTrials.gg
Sign In
RecruitingNCT03135327Updated Sep 16, 2026

Clinical Applications of Advanced Ophthalmic Imaging

An interventional study of Ocufolin in Multiple Sclerosis, Dry Eye Syndromes and Diabetic Retinopathy, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University of Miami · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 10 years 3 months after the study started (first participant enrolled Jan 2007, registered Apr 2017).
  • Started Jan 2007; still recruiting 19 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
5,000
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.

There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.

02

Conditions studied

  • Multiple Sclerosis
  • Dry Eye Syndromes
  • Diabetic Retinopathy
  • Presbyopia
  • Myopia
  • Dementia
03

In context

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

University of Miami is the lead sponsor of 840 studies on the registry; 164 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Browse University of Miami studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Observational Phase 1 Group

Inclusion Criteria:

  1. Self-reported normal healthy subjects;
  2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke;
  3. Who can keep the eye open for imaging.

Exclusion Criteria:

  1. who can not read and sign the ICF;
  2. who can not receiving ophthalmic imaging;
  3. who cannot tolerate bright light during imaging.

Interventional Phase 2 Group:

Inclusion criteria

The participant will be eligible for entry in the study if s/he:

  1. Is at least 18 years old and has full legal capacity to volunteer;
  2. Has read and signed the IRB Document;
  3. Is willing and able to follow participant instructions;
  4. Has clear corneas and crystalline lens;
  5. Initial visual acuities were 20/80 or better;
  6. MTHFR C677TT homozygous, or MTHFR C677T/A1298C compound heterozygous with mild to moderate micro-aneurismal vascular retinopathy disease;
  7. is 10 or less;
  8. Normotensive with or without medications;
  9. Without retinal capillary dropout or macular edema;
  10. Blood homocysteine > 9.

Exclusion criteria

The subjects will be ineligible for entry into the study if s/he:

  1. Has an active ocular disease;
  2. Has had surgery or an eye injury within 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    Interventional Phase - Ocufolin Group

    Participants in this group will receive the Ocufolin medical food for 6 months.

    Dietary Supplement: Ocufolin

  • No intervention
    Observational Phase Group

    Participants in this group will be studied and followed up for 1-2 years.

Interventions

  • Dietary supplementOcufolin

    Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.

06

What researchers measure

Primary outcomes

  1. Retinal microstructure using OCT.

    Optical coherence tomography is used to measure the thickness of intraretinal layers. The measurement is in micrometer.

    Time frame: up to 2 years

  2. Retinal vasculature by optical coherence tomography angiography (OCTA)

    Retinal vascular network density in percentage.

    Time frame: up to 2 years

  3. Conjunctival vasculature by functional slit-lamp (FSLB)

    Conjunctival vascular network density in percentage.

    Time frame: up to 2 years

  4. Corneal epithelial thickness

    Measured in micrometers using ultra high resolution OCT

    Time frame: up to 2 years

  5. Tear film thickness

    Measured in micrometers using ultra high resolution OCT

    Time frame: up to 2 years

Secondary outcomes

  1. Retinal blood flow velocity by retinal function imager (RFI)

    Retinal blood flow velocity in mm/s

    Time frame: up to 2 years

  2. Conjunctival blood flow velocity by functional slit-lamp (FSLB)

    Conjunctival blood flow velocity in mm/s

    Time frame: up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2007 (actual). Primary completion is estimated for Dec 2029, 275 months after the start.

Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 275 months is above that.

Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2017
First posted
May 1, 2017
StartActual
Jan 1, 2007
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03135327
Lead sponsor
University of Miami
Responsible party
Jianhua (Jay) Wang, MD, PhD (Professor, University of Miami) — Principal investigator
First posted
May 1, 2017
Start date
Jan 1, 2007
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 16, 2026

Study contacts

Jianhua Wang, MD, PhD
Contact
jwang3@med.miami.edu
3054825010
Jianhua Wang, MD, PhD
principal investigator · Bascom Palmer Eye Institute, University of Miami, Miami, FL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Sclerosis →

Other studies from this sponsor

University of Miami →

Start the discussion